China Pharma Holdings (CPHI) Debt to Equity (2016 - 2025)
China Pharma Holdings' Debt to Equity history spans 16 years, with the latest figure at $0.09 for Q4 2025.
- For Q4 2025, Debt to Equity fell 73.44% year-over-year to $0.09; the TTM value through Dec 2025 reached $0.09, down 73.44%, while the annual FY2025 figure was $0.09, 73.44% down from the prior year.
- Debt to Equity reached $0.09 in Q4 2025 per CPHI's latest filing, down from $0.24 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.62 in Q3 2022 to a low of $0.09 in Q4 2025.
- Average Debt to Equity over 5 years is $0.53, with a median of $0.41 recorded in 2021.
- Peak YoY movement for Debt to Equity: surged 119.86% in 2021, then plummeted 75.68% in 2023.
- A 5-year view of Debt to Equity shows it stood at $0.72 in 2021, then decreased by 20.9% to $0.57 in 2022, then crashed by 42.41% to $0.33 in 2023, then fell by 0.1% to $0.33 in 2024, then tumbled by 73.44% to $0.09 in 2025.
- Per Business Quant, the three most recent readings for CPHI's Debt to Equity are $0.09 (Q4 2025), $0.24 (Q3 2025), and $0.42 (Q2 2025).